DK155173B - Fremgangsmaade til fremstilling af praeparater af n-(2-furfuryl)-4-chlor-5-sulfamoyl-anthranilsyre med forsinket frigoerelse - Google Patents
Fremgangsmaade til fremstilling af praeparater af n-(2-furfuryl)-4-chlor-5-sulfamoyl-anthranilsyre med forsinket frigoerelse Download PDFInfo
- Publication number
- DK155173B DK155173B DK455274AA DK455274A DK155173B DK 155173 B DK155173 B DK 155173B DK 455274A A DK455274A A DK 455274AA DK 455274 A DK455274 A DK 455274A DK 155173 B DK155173 B DK 155173B
- Authority
- DK
- Denmark
- Prior art keywords
- furosemide
- release
- furfuryl
- sulfamoyl
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 14
- 230000003111 delayed effect Effects 0.000 title claims description 4
- 238000000034 method Methods 0.000 title description 9
- 229940079920 digestives acid preparations Drugs 0.000 title description 2
- 239000013543 active substance Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 25
- 229960003883 furosemide Drugs 0.000 description 24
- 210000002700 urine Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 210000001630 jejunum Anatomy 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FRFDWDIMSPKGJR-UHFFFAOYSA-N 6-amino-4-chloro-6-(furan-2-ylmethyl)-3-sulfamoylcyclohexa-2,4-diene-1-carboxylic acid Chemical compound C=1C=COC=1CC1(N)C=C(Cl)C(S(N)(=O)=O)=CC1C(O)=O FRFDWDIMSPKGJR-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 230000000054 salidiuretic effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2343218A DE2343218C2 (de) | 1973-08-28 | 1973-08-28 | Furosemid enthaltende Pellets |
| DE2343218 | 1973-08-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK455274A DK455274A (en, 2012) | 1975-04-28 |
| DK155173B true DK155173B (da) | 1989-02-27 |
Family
ID=5890849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK455274AA DK155173B (da) | 1973-08-28 | 1974-08-27 | Fremgangsmaade til fremstilling af praeparater af n-(2-furfuryl)-4-chlor-5-sulfamoyl-anthranilsyre med forsinket frigoerelse |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4324779A (en, 2012) |
| JP (1) | JPS563849B2 (en, 2012) |
| AT (1) | AT344914B (en, 2012) |
| BE (1) | BE819294A (en, 2012) |
| CA (1) | CA1063024A (en, 2012) |
| DE (1) | DE2343218C2 (en, 2012) |
| DK (1) | DK155173B (en, 2012) |
| EG (1) | EG14662A (en, 2012) |
| FI (1) | FI249774A7 (en, 2012) |
| FR (1) | FR2242076B1 (en, 2012) |
| GB (1) | GB1478715A (en, 2012) |
| HU (1) | HU171769B (en, 2012) |
| IL (1) | IL45521A (en, 2012) |
| MX (1) | MX3585E (en, 2012) |
| NL (1) | NL7411269A (en, 2012) |
| SE (1) | SE7410788L (en, 2012) |
| ZA (1) | ZA745443B (en, 2012) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1086226A (en) * | 1976-11-26 | 1980-09-23 | Yegnaswami Raghunathan | Ion exchange resin prolonged release pharmaceutical preparations |
| GB1561204A (en) * | 1977-06-01 | 1980-02-13 | Ici Ltd | Sustained release pharmaceutical composition |
| US4773907A (en) * | 1982-12-20 | 1988-09-27 | Alza Corporation | Primary delivery system comprising secondary dosage form |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
| DE3305935C2 (de) * | 1983-02-21 | 1985-05-30 | Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn | Kaliumneutrales Saluretikum mit antihypertensiver Wirkung |
| IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
| US4663348A (en) * | 1985-07-02 | 1987-05-05 | Warner-Lambert Co. | Furosemide salts and pharmaceutical preparations thereof |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| JPH01130957U (en, 2012) * | 1988-02-29 | 1989-09-06 | ||
| JPH0710747A (ja) * | 1993-04-28 | 1995-01-13 | Takeda Chem Ind Ltd | 固形製剤およびその製造方法 |
| GB2281697A (en) * | 1993-09-14 | 1995-03-15 | Euro Celtique Sa | Laxative compositions in capsules |
| US20070059358A1 (en) * | 2003-07-02 | 2007-03-15 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Matrix adjuvants and the drop pills prepared with them |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3058882A (en) * | 1959-12-28 | 1962-10-16 | Hoechst Ag | N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof |
| US3361632A (en) * | 1964-05-08 | 1968-01-02 | Hoechst Ag | Medicinal preparations having a protracted activity and method of making them |
| US3456049A (en) * | 1965-05-25 | 1969-07-15 | Ciba Geigy Corp | Gradual-release tablet |
| US3857933A (en) * | 1969-10-17 | 1974-12-31 | Hoechst Ag | Process for the manufacture of a drug dosage form permitting controlled release of active ingredient |
| DE2010416B2 (de) * | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
-
1973
- 1973-08-28 DE DE2343218A patent/DE2343218C2/de not_active Expired
-
1974
- 1974-08-23 IL IL45521A patent/IL45521A/xx unknown
- 1974-08-23 GB GB37157/74A patent/GB1478715A/en not_active Expired
- 1974-08-23 NL NL7411269A patent/NL7411269A/xx active Search and Examination
- 1974-08-26 SE SE7410788A patent/SE7410788L/xx unknown
- 1974-08-26 JP JP9713274A patent/JPS563849B2/ja not_active Expired
- 1974-08-26 ZA ZA00745443A patent/ZA745443B/xx unknown
- 1974-08-26 FI FI2497/74A patent/FI249774A7/fi unknown
- 1974-08-26 EG EG355/74A patent/EG14662A/xx active
- 1974-08-27 HU HU74HO00001710A patent/HU171769B/hu unknown
- 1974-08-27 MX MX742666U patent/MX3585E/es unknown
- 1974-08-27 DK DK455274AA patent/DK155173B/da not_active Application Discontinuation
- 1974-08-27 AT AT694274A patent/AT344914B/de not_active IP Right Cessation
- 1974-08-27 CA CA207,950A patent/CA1063024A/en not_active Expired
- 1974-08-28 BE BE147988A patent/BE819294A/xx not_active IP Right Cessation
- 1974-08-28 FR FR7429442A patent/FR2242076B1/fr not_active Expired
-
1979
- 1979-09-20 US US06/077,181 patent/US4324779A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FI249774A7 (en, 2012) | 1975-03-01 |
| DK455274A (en, 2012) | 1975-04-28 |
| JPS563849B2 (en, 2012) | 1981-01-27 |
| FR2242076A1 (en, 2012) | 1975-03-28 |
| MX3585E (es) | 1981-03-20 |
| CA1063024A (en) | 1979-09-25 |
| DE2343218A1 (de) | 1975-04-03 |
| JPS5076217A (en, 2012) | 1975-06-21 |
| AU7272874A (en) | 1976-03-04 |
| SE7410788L (en, 2012) | 1975-03-03 |
| HU171769B (hu) | 1978-03-28 |
| IL45521A0 (en) | 1974-11-29 |
| IL45521A (en) | 1978-07-31 |
| DE2343218C2 (de) | 1986-08-07 |
| FR2242076B1 (en, 2012) | 1978-07-28 |
| AT344914B (de) | 1978-08-25 |
| ZA745443B (en) | 1975-08-27 |
| GB1478715A (en) | 1977-07-06 |
| EG14662A (en) | 1984-09-30 |
| NL7411269A (nl) | 1975-03-04 |
| ATA694274A (de) | 1977-12-15 |
| US4324779A (en) | 1982-04-13 |
| BE819294A (fr) | 1975-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3194974B2 (ja) | 標的制御釈放薬剤 | |
| AU609916B2 (en) | Sustained release pharmaceutical composition | |
| DK174949B1 (da) | Formuleringer med forlænget frigivelse og deres fremstilling | |
| US4752470A (en) | Controlled release indomethacin | |
| EP0519870B1 (de) | Neue orale Diclofenaczubereitung | |
| FI78835B (fi) | Foerfarande foer framstaellning av en ny dipyridamol-retardform. | |
| DK155173B (da) | Fremgangsmaade til fremstilling af praeparater af n-(2-furfuryl)-4-chlor-5-sulfamoyl-anthranilsyre med forsinket frigoerelse | |
| RU2240110C2 (ru) | Новый препарат | |
| EP0339506B1 (de) | Orales osmotisches System mit verbesserter Haftwirkung der Membran am Kern | |
| PL188834B1 (pl) | Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji | |
| US5468503A (en) | Oral pharmaceutical preparation released at infragastrointestinal tract | |
| JPH03112930A (ja) | ミノサイクリンの脈動性１日１回放出系 | |
| EP0339420B1 (de) | DHP-Retard-Zubereitung | |
| PT85525B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo uma mistura de 2,6-bis-(dietanolamino)-4,8-dipiperidino-(5,4-d)-pirimidina (dipiridamol) ou de 2,6-bis-(dietanolamino)-8-piperidino-(5,4-d)-pirimidina (mopidamol) ou um dos seus sais fisiologicamente aceitaveis com acido o-acetilsalicilico | |
| NO166063B (no) | Baerebelegg til belegging av et medikament for oppnaaelse av et farmasoeytisk preparat med forlenget frigivelse. | |
| FI86373B (fi) | Belaeggning foer en farmaceutiskt tablett med foerdroejd effekt och foerfarande foer framstaellning av en tablett. | |
| JP2599189B2 (ja) | 味覚遮蔽剤を含有している咀嚼可能な薬物錠剤 | |
| US4155993A (en) | Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use | |
| KR20100098612A (ko) | 개선된 정제 코팅 | |
| DK164843B (da) | Theophyllin-retardpraeparat og fremgangsmaade til fremstilling heraf | |
| CN106176652A (zh) | 一种盐酸二甲双胍缓释片及其制备方法 | |
| RU2411035C2 (ru) | Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината | |
| JP3282832B2 (ja) | 持続性錠剤 | |
| US20060165808A1 (en) | Microcapsules for the delayed, controlled release of perindopril | |
| AU2007233759A1 (en) | Oral pharmaceutical coated composition for pulsatile release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PRF | Application refused |